Editorial
. 2010 May;75(5):1114; author reply 1115.
doi: 10.1016/j.urology.2009.07.1290.
Editorial comment
- PMID: 20451726
- DOI: 10.1016/j.urology.2009.07.1290
Item in Clipboard
Editorial
Editorial comment
Urology.
2010 May.
No abstract available
Comment on
-
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.Urology. 2010 May;75(5):1108-13.e1. doi: 10.1016/j.urology.2009.06.105. Epub 2009 Nov 20. Urology. 2010. PMID: 19931124
Similar articles
-
Editorial comment.Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291. Urology. 2010. PMID: 20451727 No abstract available.
-
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844. Clin Cancer Res. 2007. PMID: 17606705 Review. No abstract available.
-
Two new drugs for renal cell carcinoma.Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20. Med Lett Drugs Ther. 2007. PMID: 17325624 No abstract available.
-
Trials probe new agents for kidney cancer.JAMA. 2006 Jul 12;296(2):155-7. doi: 10.1001/jama.296.2.155. JAMA. 2006. PMID: 16835411 No abstract available.
-
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.BJU Int. 2007 May;99(5 Pt B):1223-9. doi: 10.1111/j.1464-410X.2007.06814.x. BJU Int. 2007. PMID: 17441915 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
